Unknown

Dataset Information

0

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.


ABSTRACT: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long been debated. Based on recent promising clinical results from CD20-depleting strategies by three therapeutic monoclonal antibodies in clinical phase II and III trials (rituximab, ocrelizumab and ofatumumab), targeting B cells in MS is currently attracting growing interest among basic researchers and clinicians. Many questions about the role of B and plasma cells in MS remain still unanswered, ranging from the role of specific B-cell subsets and functions to the optimal treatment regimen of B-cell depletion and monitoring thereafter. Here, we will assess our current knowledge of the mechanisms implicating B cells in multiple steps of disease pathology and examine current and future therapeutic approaches for the treatment of MS.

SUBMITTER: Bittner S 

PROVIDER: S-EPMC5400151 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management.

Bittner Stefan S   Ruck Tobias T   Wiendl Heinz H   Grauer Oliver M OM   Meuth Sven G SG  

Therapeutic advances in neurological disorders 20160902 1


Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease that is caused by an autoimmune response against central nervous system (CNS) structures. Traditionally considered a T-cell-mediated disorder, the contribution of B cells to the pathogenesis of MS has long been debated. Based on recent promising clinical results from CD20-depleting strategies by three therapeutic monoclonal antibodies in clinical phase II and III trials (rituximab, ocrelizumab and ofatumumab), targeting B ce  ...[more]

Similar Datasets

| S-EPMC5794695 | biostudies-other
| S-EPMC10401910 | biostudies-literature
2015-03-10 | GSE66573 | GEO
2015-03-10 | E-GEOD-66573 | biostudies-arrayexpress
| S-EPMC5574272 | biostudies-literature
| S-EPMC4473119 | biostudies-literature
| S-EPMC4403723 | biostudies-literature
| S-EPMC4522024 | biostudies-literature
| S-EPMC3699254 | biostudies-other
| S-EPMC3503813 | biostudies-literature